Month: October 2022

Imidazole derivatives generally have good solubility in protic solvents. Simple imidazole derivatives, such as 1H-imidazole, 2-methyl-1H-imidazole, and 1,2-dimethylimidazole, have very high solubility in water. 10111-08-7, formula is C4H4N2O, Name is 1H-Imidazole-2-carbaldehyde. Their solubility in alcohol is lower than that in water and decreases with increasing molecular weight of the alcohols . Recommanded Product: 1H-Imidazole-2-carbaldehyde.

Wang, Jian Hua;Liu, Yao Ming;Chao, Jian Bin;Wang, Yu;Wang, Hui;Shuang, Shao Min research published 《 A phenazine-imidazole based ratiometric fluorescent probe for Cd²⁺ ions and its application in in vivo imaging》, the research content is summarized as follows. A new phenazine-imidazole based Schiff base (PIS) fluorescent probe has been developed for the ratiometric detection of Cd²⁺ ions in aqueous media at physiol. pH. PIS upon binding with Cd²⁺ ions shows red shifted fluorescence and thereby, permits ratiometric detection of Cd(II) ions. A detection limit down to 2.10 x 10^-8 M was determined for Cd²⁺ quantitation. Also, the accompanying apparent fluorescence color change (from yellow to orange red) is noticeable to the naked eye under a UV-lamp. The sensing mechanism could be attributed to the 1 : 1 PIS-Cd complexation, followed by extension of the conjugation due to better planarity and modulation of the charge transfer efficiency in the probe. This was complemented by solvatochromism and d. functional theory calculations Furthermore, PIS was used to detect Cd²⁺ in Oxya chinensis cells, zebrafish larvae and live tissues of Arabidopsis thaliana under a fluorescence microscope, showing great potential in analyzing living biosystems.

Recommanded Product: 1H-Imidazole-2-carbaldehyde, 1H-Imidazole-2-carbaldehyde, also known as 1H-Imidazole-2-carbaldehyde, is a useful research compound. Its molecular formula is C4H4N2O and its molecular weight is 96.09 g/mol. The purity is usually 95%.
1H-Imidazole-2-carboxaldehyde is a novel PTP1b inhibitor with potential application to treat type 2 diabetes.
1H-Imidazole-2-carboxaldehyde is a broad-spectrum antimicrobial that has been shown to inhibit the growth of bacteria by interfering with protein synthesis. It binds to the cytosolic protein and receptor molecule, which are involved in the activation of bacterial enzymes. Imidazole-2-carboxaldehyde reacts with anhydrous sodium and copper complex to produce hydrogen bonds, which prevent the formation of the nitrogen atoms necessary for cellular processes. This chemical also has biological properties such as glyoxal, which inhibits bacterial growth by reacting with amino groups on proteins., 10111-08-7.

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Imidazole Biochem/physiol Actions: Imidazole derivatives have antibacterial, antifungal and anticancer functionality. It interacts with DNA and also binds to protein and stops cell division. 10111-08-7, formula is C4H4N2O, Name is 1H-Imidazole-2-carbaldehyde. It also acts as a microtubule destabilizing agents and inhibits topoisomerase and Cytochrome P450 Family 26 Subfamily A Member 1 (CYP26A1) enzymes. Formula: C4H4N2O.

Wang, Huanhuan;Bao, Yuheng;Qiu, Huiqiang;Tong, Weijun research published 《 Encapsulation of Methylene Blue in Zeolitic Imidazolate Framework-90 Nanoparticles to Protect Its Photodynamic Activity》, the research content is summarized as follows. Methylene blue (MB) is widely used as a photosensitizer in photodynamic therapy applications. However, it is easily reduced by reductases in biol. environments, which hampers its further applications. Here, we developed a one-pot method to synthesize MB-encapsulated and poly(vinylpyrrolidone) (PVP)-modified zeolitic imidazolate framework-90 (ZIF-90) nanoparticles (MB@ZIF-90/PVP NPs). The NPs show intact crystalline structure with improved colloidal dispersity and stability both in water and in the medium for cell culture. The size of the enzymes is much larger than the pore size of ZIF-90; thus, the access of reductive enzymes to encapsulated MB is prohibited, resulting in the protection of MB′s photodynamic activity. Furthermore, cell experiments confirm that MB@ZIF-90/PVP NPs have lower dark cytotoxity than equivalent free MB but can efficiently induce photodynamic damage to tumor cells even in the presence of reductive enzymes upon light irradiation

10111-08-7, 1H-Imidazole-2-carbaldehyde, also known as 1H-Imidazole-2-carbaldehyde, is a useful research compound. Its molecular formula is C4H4N2O and its molecular weight is 96.09 g/mol. The purity is usually 95%.
1H-Imidazole-2-carboxaldehyde is a novel PTP1b inhibitor with potential application to treat type 2 diabetes.
1H-Imidazole-2-carboxaldehyde is a broad-spectrum antimicrobial that has been shown to inhibit the growth of bacteria by interfering with protein synthesis. It binds to the cytosolic protein and receptor molecule, which are involved in the activation of bacterial enzymes. Imidazole-2-carboxaldehyde reacts with anhydrous sodium and copper complex to produce hydrogen bonds, which prevent the formation of the nitrogen atoms necessary for cellular processes. This chemical also has biological properties such as glyoxal, which inhibits bacterial growth by reacting with amino groups on proteins., Formula: C4H4N2O

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Imidazole based anticancer drug find applications in cancer chemotherapy. 3034-50-2, formula is C4H4N2O, Name is Imidazole-4-carbaldehyde. It is used as buffer component for purification of the histidine tagged recombinant proteins in immobilized metal-affinity chromatography (IMAC). Quality Control of 3034-50-2.

Wang, Huan;Wong, Alison;Lewis, Luke C.;Nemeth, Genevieve R.;Jordan, Veronica Clavijo;Bacon, Jeffrey W.;Caravan, Peter;Shafaat, Hannah S.;Gale, Eric M. research published 《 Rational Ligand Design Enables pH Control over Aqueous Iron Magnetostructural Dynamics and Relaxometric Properties》, the research content is summarized as follows. Complexes of Fe³⁺ engage in rich aqueous solution speciation chem. in which discrete mols. can react with solvent water to form multinuclear μ-oxo and μ-hydroxide bridged species. Here we demonstrate how pH- and concentration-dependent equilibration between monomeric and μ-oxo-bridged dimeric Fe³⁺ complexes can be controlled through judicious ligand design. We purposed this chem. to develop a first-in-class Fe³⁺-based MR imaging probe, Fe-PyCy2AI, that undergoes relaxivity change via pH-mediated control of monomer vs dimer speciation. The monomeric complex exists in a S = 5/2 configuration capable of inducing efficient T₁-relaxation, whereas the antiferromagnetically coupled dimeric complex is a much weaker relaxation agent. The mechanisms underpinning the pH dependence on relaxivity were interrogated by using a combination of pH potentiometry, ¹H and ¹⁷O relaxometry, electronic absorption spectroscopy, bulk magnetic susceptibility, ESR spectroscopy, and X-ray crystallog. measurements. Taken together, the data demonstrate that PyCy2AI forms a ternary complex with high-spin Fe³⁺ and a rapidly exchanging water coligand, [Fe(PyCy2AI)(H₂O)]⁺ (ML), which can deprotonate to form the high-spin complex [Fe(PyCy2AI)(OH)] (ML(OH)). Under titration conditions of 7 mM Fe complex, water coligand deprotonation occurs with an apparent pK_a 6.46. Complex ML(OH) dimerizes to form the antiferromagnetically coupled dimeric complex [(Fe(PyCy2AI))₂O] ((ML)₂O) with an association constant (K_a) of 5.3 ± 2.2 mM^-1. The relaxivity of the monomeric complexes are between 7- and 18-fold greater than the antiferromagnetically coupled dimer at applied field strengths ranging between 1.4 and 11.7 T. ML(OH) and (ML)₂O interconvert rapidly within the pH 6.0-7.4 range that is relevant to human pathophysiol., resulting in substantial observed relaxivity change. Controlling Fe³⁺ μ-oxo bridging interactions through rational ligand design and in response to local chem. environment offers a robust mechanism for biochem. responsive MR signal modulation. We demonstrate how pH- and concentration-dependent equilibration between monomeric and μ-oxo-bridged dimeric Fe³⁺ complexes can be controlled through judicious ligand design. We purposed this chem. to develop a first-in-class Fe³⁺-based MR imaging probe, Fe-PyCy2AI, that undergoes relaxivity change via pH-mediated control of S = 5/2 monomer vs antiferromagnetically coupled dimer speciation.

Quality Control of 3034-50-2, 1H-Imidazole-4-carbaldehyde, also known as 1H-Imidazole-4-carbaldehyde, is a useful research compound. Its molecular formula is C4H4N2O and its molecular weight is 96.09 g/mol. The purity is usually 95%.
The starting material for a practical synthesis of a potent C17,20-lyase inhibitor. The lyase is a key enzyme in androgen biosynthesis as well as a target for treatment of androgen-dependent prostate cancer. Used to synthesize potent antimalarial drug.
1H-Imidazole-4-carbaldehyde is a chemical compound that has been shown to bind to the glucocorticoid receptor. It was synthesized by reacting 1,2-diaminobenzene with formaldehyde and then hydrolyzing the intermediate imidazolium salt, which is stable in acidic solutions. The complex can be prepared by mixing two solutions of imidazole and trifluoroacetic acid. The ligand has a redox potential of -0.1 V (vs NHE). This means it can be oxidized to the carbonyl group or reduced back to the imidazole ring. The compound is stable in neutral solution and forms stable complexes with metal ions such as Cu+, Fe3+, and Zn2+. It also coordinates well with oxygen atoms, nitrogen atoms, and water molecules. 1H-Imidazole-4-carbaldehyde has been shown to bind to glucocortic, 3034-50-2.

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Imidazole Biochem/physiol Actions: Imidazole derivatives have antibacterial, antifungal and anticancer functionality. It interacts with DNA and also binds to protein and stops cell division. 250285-32-6, formula is C27H37ClN2, Name is 1,3-Bis(2,6-diisopropylphenyl)imidazolium chloride. It also acts as a microtubule destabilizing agents and inhibits topoisomerase and Cytochrome P450 Family 26 Subfamily A Member 1 (CYP26A1) enzymes. Quality Control of 250285-32-6.

Wang, Fei;Su, Yanning;Li, Yuanzhen;Wei, Dongyuan;Sun, Hanxue;Zhu, Zhaoqi;Liang, Weidong;Li, An research published 《 Salt-Resistant Photothermal Materials Based on Monolithic Porous Ionic Polymers for Efficient Solar Steam Generation》, the research content is summarized as follows. The exploitation of salt-resistant photothermal materials is of great importance for practical solar desalination. Herein, we report, for the first time, the synthesis of monolithic porous ionic polymers (PIPs) coated with polypyrrole (PPy) as self-desalting photothermal materials for efficient solar steam generation. Based on their good thermal insulation, the desired mesopores, and the extremely high light absorption (98%), the PPy-coated PIPs exhibit a high evaporation efficiency of 89% under 1 sun irradiation and superior durability in terms of evaporation efficiency in high-salinity (30 wt %) brine. Quite different from the existing salt-resistant photothermal materials by the artificial creation of aligned channels or Janus wettability, interestingly, the self-desalting of our materials depends on their intrinsically porous ionic framework, which could serve as “ions barrier” to shield the cations of saline solution These findings may provide an opportunity for future design and fabrication of self-desalting photothermal materials by only one-pot synthesis without a further complicated process.

Quality Control of 250285-32-6, 1,3-Bis(2,6-diisopropylphenyl)imidazolium chloride, also known as 1,3-Bis(2,6-diisopropylphenyl)imidazolium chloride, is a useful research compound. Its molecular formula is C27H37ClN2 and its molecular weight is 425 g/mol. The purity is usually 95%.

1,3-Bis(2,6-diisopropylphenyl)imidazolium chloride has been used to generate N-heterocyclic carbene catalysts for use in carbonylative cross-coupling of pyridyl halides with aryl boronic acids.

1,3-Bis(2,6-diisopropylphenyl)imidazolium Chloride is an imidazolium salt that is active against all stages of Trypanosoma cruzi and may represent a promising candidate for treatment of Chagas disease.

1,3-Bis(2,6-diisopropylphenyl)imidazolium chloride is an organic compound that is used as a solvent. It was originally synthesized by reacting triethyl orthoformate with 2,6-diisopropylaniline. This reaction formed the corresponding imidazolium salt. The synthesis of this compound was later improved by using ring-opening polymerization of glycolide and furfural. 1,3-Bis(2,6-diisopropylphenyl)imidazolium chloride is mainly used to extract estradiol from urine samples in clinical laboratories., 250285-32-6.

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Imidazole Biochem/physiol Actions: Imidazole derivatives have antibacterial, antifungal and anticancer functionality. It interacts with DNA and also binds to protein and stops cell division. 60-56-0, formula is C4H6N2S, Name is 1-Methyl-1H-imidazole-2(3H)-thione. It also acts as a microtubule destabilizing agents and inhibits topoisomerase and Cytochrome P450 Family 26 Subfamily A Member 1 (CYP26A1) enzymes. Category: imidazoles-derivatives.

Vuijk, Floris A.;de Bruin, Christiaan;Peeters-Scholte, Cacha M. P. C. D.;Notting, Irene C. research published 《 Recurrent Intracranial Hypertension in a Toddler with Graves’ Disease》, the research content is summarized as follows. Idiopathic intracranial hypertension (IIH) is characterized by increased intracranial pressure without an evident cause. Obesity and the female sex have been recognized as risk factors for the development of this syndrome. Until now, Graves disease has only been described in the literature as the probable cause of IIH in 7 patients. This report describes the case of a young girl with Graves disease presenting with symptoms of intracranial hypertension (IH). A 21-mo-old girl presented with progressive symptoms of poor weight gain and bilateral exophthalmos. She also experienced difficulty sleeping, diarrhea multiple times per day, irritability, and heat intolerance. Laboratory investigation showed elevated free T4, fully suppressed TSH, and elevated anti-TSH antibodies, consistent with a diagnosis of new-onset Graves disease. She was successfully treated with monotherapy thiamazole, titrated to the lowest possible dose of 1.25 mg once daily with normalization of thyroid function tests within 3 mo of treatment initiation. After 18 mo of treatment, her condition unexpectedly deteriorated as papilledema and slight esotropia were found at a routine checkup. An MRI and lumbar puncture showed increased intracranial pressure, but no underlying anatomical cause for the IH was found. Acetazolamide therapy was started, and papilledema in both eyes resolved within weeks. Unfortunately, papilledema has recurred several times over the following 2 years when attempts were made to decrease the acetazolamide dose. This case report is the first to describe a very young patient who developed significant IIH in the chronic stage of Graves disease. IIH development seemed to be related to the progression of the Graves ophthalmopathy, rather than initiation of thiamazole therapy or fluctuations in serum fT4 levels.

Category: imidazoles-derivatives, Methimazole is an antithyroid compound found to have antioxidant properties. Methimazole inhibits activation of the IFN-g-induced Janus kinase (JAK)/STAT signaling pathway in FRTL-5 thyroid cells, which may account for its immunodolulatory effects. Additionally, methimazole is an inhibitor of thyroperoxidase.

Methimazole is a thiourea antithyroid agent that prevents iodine organification, thus inhibiting the synthesis of thyroxine. Antihyperthyroid.

Methimazole is an inhibitor of thyroid hormone synthesis. It is a substrate for thyroid peroxidase that traps oxidized iodide, preventing its use by thyroglobulin for thyroid hormone synthesis. Methimazole (0.4 mg/kg) inhibits the absorption of radiolabeled iodide by the thyroid gland in rats by 80.9%.3 It reduces the incidence of lymphocytic thyroiditis in the insulin-dependent type 1 diabetic BB/W rat. Methimazole has been used to induce hypothyroidism in mice. Formulations containing methimazole have been used in the treatment of hyperthyroidism.

Methimazole is a thyreostatic compound, and an antihormone, which is widely used in medicine for the treatment of hyperthyroidism.

Methimazole is a thioamide inhibitor of the enzyme thyroid peroxidase (TPO), with antithyroid activity. Upon administration, methimazole inhibits the metabolism of iodide and the iodination of tyrosine residues in the thyroid hormone precursor thyroglobulin by TPO; this prevents the synthesis of the thyroid hormones triiodothyronine (T3) and thyroxine (T4).

Methimazole is an antithyroid medication which is now considered the first line agent for medical therapy of hyperthyroidism and Graves disease. Methimazole has been linked to serum aminotransferase elevations during therapy as well as to a clinically apparent, idiosyncratic liver injury that is typically cholestatic and self-limited in course.
Methimazole, also known as tapazole or danantizol, belongs to the class of organic compounds known as imidazolethiones. These are aromatic compounds containing an imidazole ring which bears a thioketone group. Methimazole is a drug which is used for the treatment of hyperthyroidism, goiter, graves disease and psoriasis. Methimazole is soluble (in water) and a very weakly acidic compound (based on its pKa). Methimazole has been detected in multiple biofluids, such as urine and blood. Methimazole can be converted into methimazole S-oxide., 60-56-0.

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Imidazole is a heterocyclic compound with a five-membered planar ring. It is amphoteric and highly polar. 60-56-0, formula is C4H6N2S, Name is 1-Methyl-1H-imidazole-2(3H)-thione. The pharmacophore of imidazole exists in bioactive compounds including amino acids, plant growth regulators and therapeutic agents. Electric Literature of 60-56-0.

von Itzstein, Mitchell S.;Gonugunta, Amrit S.;Wang, Yiqing;Sheffield, Thomas;Lu, Rong;Ali, Sadia;Fattah, Farjana J.;Xie, Donglu;Cai, Jennifer;Xie, Yang;Gerber, David E. research published 《 Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors》, the research content is summarized as follows. Thyroid dysfunction is among the most common autoimmune diseases and immune checkpoint inhibitor (ICI)-induced immune-related adverse events (irAE). We determined the association between longitudinal thyroid function and clin. outcomes in patients treated with ICI. We identified all patients treated with ICI at UT Southwestern Medical Center from Jan. 1, 2011, through Dec. 31, 2020. We defined normal TSH (TSH) and free thyroxine (FT4) levels according to institutional reference range. We defined clin. thyroid dysfunction using established criteria incorporating labs and treatment. We determined the association between thyroid function and overall survival (OS) using Kaplan-Meier curves, log-rank tests, and multivariate Cox proportional hazards model. A total of 1781 patients were included in analyses, of whom 381 (21%) had abnormal baseline TSH. Patients with abnormal baseline TSH were more likely to be female, have kidney cancer, and initiate levothyroxine after ICI initiation (all P < 0.001). Patients with abnormal baseline TSH had inferior OS (median 16 vs 27 mo; P < 0.001). Among patients with normal baseline TSH, those who had abnormal TSH after ICI initiation had improved OS (median 41 vs 22 mo; P < 0.001). In a multivariate Cox model, abnormal baseline TSH was associated with worse OS (HR 1.62; 95% CI, 1.30-2.02; P < 0.001), while initiation of levothyroxine after ICI initiation was associated with improved OS (HR 0.62; 95% CI, 0.44-0.88; P = 0.008). ICI-induced thyroid dysfunction is associated with improved survival, although abnormal TSH prior to ICI initiation is associated with inferior survival. Precis: Thyroid abnormalities occur commonly in the general population and as immunotherapy toxicities. We found that immunotherapy-induced thyroid dysfunction is associated with better survival, but pre-existing thyroid abnormalities convey worse outcomes.

60-56-0, Methimazole is an antithyroid compound found to have antioxidant properties. Methimazole inhibits activation of the IFN-g-induced Janus kinase (JAK)/STAT signaling pathway in FRTL-5 thyroid cells, which may account for its immunodolulatory effects. Additionally, methimazole is an inhibitor of thyroperoxidase.

Methimazole is a thiourea antithyroid agent that prevents iodine organification, thus inhibiting the synthesis of thyroxine. Antihyperthyroid.

Methimazole is an inhibitor of thyroid hormone synthesis. It is a substrate for thyroid peroxidase that traps oxidized iodide, preventing its use by thyroglobulin for thyroid hormone synthesis. Methimazole (0.4 mg/kg) inhibits the absorption of radiolabeled iodide by the thyroid gland in rats by 80.9%.3 It reduces the incidence of lymphocytic thyroiditis in the insulin-dependent type 1 diabetic BB/W rat. Methimazole has been used to induce hypothyroidism in mice. Formulations containing methimazole have been used in the treatment of hyperthyroidism.

Methimazole is a thyreostatic compound, and an antihormone, which is widely used in medicine for the treatment of hyperthyroidism.

Methimazole is a thioamide inhibitor of the enzyme thyroid peroxidase (TPO), with antithyroid activity. Upon administration, methimazole inhibits the metabolism of iodide and the iodination of tyrosine residues in the thyroid hormone precursor thyroglobulin by TPO; this prevents the synthesis of the thyroid hormones triiodothyronine (T3) and thyroxine (T4).

Methimazole is an antithyroid medication which is now considered the first line agent for medical therapy of hyperthyroidism and Graves disease. Methimazole has been linked to serum aminotransferase elevations during therapy as well as to a clinically apparent, idiosyncratic liver injury that is typically cholestatic and self-limited in course.
Methimazole, also known as tapazole or danantizol, belongs to the class of organic compounds known as imidazolethiones. These are aromatic compounds containing an imidazole ring which bears a thioketone group. Methimazole is a drug which is used for the treatment of hyperthyroidism, goiter, graves disease and psoriasis. Methimazole is soluble (in water) and a very weakly acidic compound (based on its pKa). Methimazole has been detected in multiple biofluids, such as urine and blood. Methimazole can be converted into methimazole S-oxide., Electric Literature of 60-56-0

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Imidazole based anticancer drug find applications in cancer chemotherapy. 1739-84-0, formula is C5H8N2, Name is 1,2-Dimethyl-1H-imidazole. It is used as buffer component for purification of the histidine tagged recombinant proteins in immobilized metal-affinity chromatography (IMAC). Computed Properties of 1739-84-0.

Vieira, Michele O.;Monteiro, Wesley F.;Ferreira, Thuany M.;Domingos, Josiel B.;Dupont, Jairton;dos Santos, Francisco P.;Scholten, Jackson D. research published 《 Surface active SNS-based dicationic ionic liquids containing amphiphilic anions: Experimental and theoretical studies of their structures and organization in solution》, the research content is summarized as follows. Surface active ionic liquids (SAILs) have been reported as new media that collectively offer the advantages of the aqueous and oily phases. In particular, dicationic ionic liquids (DILs) have attracted much interests because their tunable physicochem. properties allow them to act as sustainable active catalysts in chem. reactions (CO₂ conversion, esterification) and also as extraction media to remove drugs/pollutants from aqueous systems. In order to better understand this class of ILs, this work describes new strategies for the synthesis of SNS-based dicationic ILs containing amphiphilic anions ([C₁₂SO₄]^–, [C₁₂ESO₄]^–, [C₁₂BSO₃]^–and [C₁₂SAR]^–) and the evaluation of their structural organization and aggregation level in solution The results obtained by exptl. techniques (FTIR, TGA, DSC, POM, ESI-MS, DLS and NMR) combined with those achieved by theor. DFT calculations revealed that the anion has an important function to modulate the properties of the SNS-based ILs in solution, while the presence of a Me group at the C2 position of the imidazolium ring seems to be not sufficient to change such physicochem. properties. The ILs containing the anion [CC₁₂BSO₃]^– showed a superior ionic organization in solution due to the cationic aggregates observed in the ESI(+) mode and the large size of aggregates observed by DLS. This behavior may be assigned to a close proximity of the cationic imidazolium ring and the aromatic ring in the anion (π-π interaction), and by NMR anal. (ROESY and DOSY) it was possible to confirm interactions between cation and anion. Therefore, the theor. and exptl. results obtained for the SNS-based dicationic ILs containing amphiphilic anions indicate that these ILs can be applied as media in both pure and/or solution systems for many sustainable applications.

Computed Properties of 1739-84-0, 1,2-Dimethylimidazole is used in the synthesis of 1,2-dimethyl-3-n-butylimidazoliumchloride and 1,2-dimethyl-3-n-propylimidazolium chloride. It also can be used in the synthesis of 1-(2-methoxyethyl)-2,3-dimethylimidazolium chloride and hexafluorophosphate salts.
1,2-Dimethylimidazole is a heterocyclic compound that contains nitrogen and carbon. It can be produced by the reaction between glyoxal and fatty acid in the presence of a base. 1,2-Dimethylimidazole has been shown to have biological properties such as an antioxidant effect. It is also used as a chemical intermediate for production of other chemicals such as 2-methylimidazole and 3-methylimidazole. 1,2-Dimethylimidazole has been shown to react with metal carbonyls to produce methylimines, which are useful intermediates in organic synthesis. The reaction mechanism involves hydrogen bonding and steric interactions between the imidazole ring and the metal carbonyl reactant., 1739-84-0.

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Imidazole is a five-membered heterocyclic moiety that possesses three carbon, two nitrogen, four hydrogen atoms, and two double bonds. 250285-32-6, formula is C27H37ClN2, Name is 1,3-Bis(2,6-diisopropylphenyl)imidazolium chloride. It is also known as 1, 3-diazole. It contains two nitrogen atoms, in which one nitrogen bear a hydrogen atom, and the other is called pyrrole type nitrogen. SDS of cas: 250285-32-6.

Vermersch, Francois;Yazdani, Sima;Junor, Glen P.;Grotjahn, Douglas B.;Jazzar, Rodolphe;Bertrand, Guy research published 《 Stable Singlet Carbenes as Organic Superbases》, the research content is summarized as follows. A simple exptl. procedure for scaling carbene Bronsted basicity was described. The results highlighted the strong basicity of pyrazol-4-ylidenes, a type of mesoionic carbene, also named cyclic-bentallenes (CBA). They were more basic (pK_aH >42.7 in acetonitrile) than the popular proazaphosphatrane Verkade bases and even the Schwesinger phosphazene superbase P₄(^tBu). The basicity of these compounds can readily be tuned, and they are accessible in multigram quantities. These results open new avenues for carbon centered superbases.

SDS of cas: 250285-32-6, 1,3-Bis(2,6-diisopropylphenyl)imidazolium chloride, also known as 1,3-Bis(2,6-diisopropylphenyl)imidazolium chloride, is a useful research compound. Its molecular formula is C27H37ClN2 and its molecular weight is 425 g/mol. The purity is usually 95%.

1,3-Bis(2,6-diisopropylphenyl)imidazolium chloride has been used to generate N-heterocyclic carbene catalysts for use in carbonylative cross-coupling of pyridyl halides with aryl boronic acids.

1,3-Bis(2,6-diisopropylphenyl)imidazolium Chloride is an imidazolium salt that is active against all stages of Trypanosoma cruzi and may represent a promising candidate for treatment of Chagas disease.

1,3-Bis(2,6-diisopropylphenyl)imidazolium chloride is an organic compound that is used as a solvent. It was originally synthesized by reacting triethyl orthoformate with 2,6-diisopropylaniline. This reaction formed the corresponding imidazolium salt. The synthesis of this compound was later improved by using ring-opening polymerization of glycolide and furfural. 1,3-Bis(2,6-diisopropylphenyl)imidazolium chloride is mainly used to extract estradiol from urine samples in clinical laboratories., 250285-32-6.

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Imidazole based anticancer drug find applications in cancer chemotherapy. 60-56-0, formula is C4H6N2S, Name is 1-Methyl-1H-imidazole-2(3H)-thione. It is used as buffer component for purification of the histidine tagged recombinant proteins in immobilized metal-affinity chromatography (IMAC). Electric Literature of 60-56-0.

Verma, Kanika;Lahariya, Ayush K.;Dubey, Shivangee;Verma, Anil K.;Das, Aparup;Schneider, Kristan A.;Bharti, Praveen K. research published 《 An integrated virtual screening and drug repurposing strategy for the discovery of new antimalarial drugs against Plasmodium falciparum phosphatidylinositol 3-kinase》, the research content is summarized as follows. The emergence and spread of drug resistance in Plasmodium falciparum, the parasite causing the most severe form of human malaria, is a major threat to malaria control and elimination programs around the globe. With P. falciparum having evolved widespread resistance against a number of previously widely used drugs, currently, artemisinin (ART) and its derivatives are the cornerstones of first-line treatments of uncomplicated malaria. However, growing incidences of ART failure reflect the spread of ART-resistant P. falciparum strains. Despite current efforts to understand the primary cause of ART resistance due to mutations in the Kelch 13 gene (PfK13), the mechanism underlying ART resistance is still not completely unclear and no feasible strategies to counteract the causes and thereby restoring the efficiency of ART have been developed. We use a polypharmacol. approach to identify potential drugs that can be used for the novel purpose (target). Of note, we have designed a multimodal stratagem to identify approved drugs with a potential antimalarial activity using computational drug reprofiling. Our investigations suggest that oxetacaine, simvastatin, repaglinide, aclidinium, propafenone, and lovastatin could be repurposed for malaria control and prevention.

60-56-0, Methimazole is an antithyroid compound found to have antioxidant properties. Methimazole inhibits activation of the IFN-g-induced Janus kinase (JAK)/STAT signaling pathway in FRTL-5 thyroid cells, which may account for its immunodolulatory effects. Additionally, methimazole is an inhibitor of thyroperoxidase.

Methimazole is a thiourea antithyroid agent that prevents iodine organification, thus inhibiting the synthesis of thyroxine. Antihyperthyroid.

Methimazole is an inhibitor of thyroid hormone synthesis. It is a substrate for thyroid peroxidase that traps oxidized iodide, preventing its use by thyroglobulin for thyroid hormone synthesis. Methimazole (0.4 mg/kg) inhibits the absorption of radiolabeled iodide by the thyroid gland in rats by 80.9%.3 It reduces the incidence of lymphocytic thyroiditis in the insulin-dependent type 1 diabetic BB/W rat. Methimazole has been used to induce hypothyroidism in mice. Formulations containing methimazole have been used in the treatment of hyperthyroidism.

Methimazole is a thyreostatic compound, and an antihormone, which is widely used in medicine for the treatment of hyperthyroidism.

Methimazole is a thioamide inhibitor of the enzyme thyroid peroxidase (TPO), with antithyroid activity. Upon administration, methimazole inhibits the metabolism of iodide and the iodination of tyrosine residues in the thyroid hormone precursor thyroglobulin by TPO; this prevents the synthesis of the thyroid hormones triiodothyronine (T3) and thyroxine (T4).

Methimazole is an antithyroid medication which is now considered the first line agent for medical therapy of hyperthyroidism and Graves disease. Methimazole has been linked to serum aminotransferase elevations during therapy as well as to a clinically apparent, idiosyncratic liver injury that is typically cholestatic and self-limited in course.
Methimazole, also known as tapazole or danantizol, belongs to the class of organic compounds known as imidazolethiones. These are aromatic compounds containing an imidazole ring which bears a thioketone group. Methimazole is a drug which is used for the treatment of hyperthyroidism, goiter, graves disease and psoriasis. Methimazole is soluble (in water) and a very weakly acidic compound (based on its pKa). Methimazole has been detected in multiple biofluids, such as urine and blood. Methimazole can be converted into methimazole S-oxide., Electric Literature of 60-56-0

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Imidazole Biochem/physiol Actions: Imidazole derivatives have antibacterial, antifungal and anticancer functionality. It interacts with DNA and also binds to protein and stops cell division. 10111-08-7, formula is C4H4N2O, Name is 1H-Imidazole-2-carbaldehyde. It also acts as a microtubule destabilizing agents and inhibits topoisomerase and Cytochrome P450 Family 26 Subfamily A Member 1 (CYP26A1) enzymes. Recommanded Product: 1H-Imidazole-2-carbaldehyde.

Velasquez-Hernandez, Miriam de J.;Astria, Efwita;Winkler, Sarah;Liang, Weibin;Wiltsche, Helmar;Poddar, Arpita;Shukla, Ravi;Prestwich, Glenn;Paderi, John;Salcedo-Abraira, Pablo;Amenitsch, Heinz;Horcajada, Patricia;Doonan, Christian J.;Falcaro, Paolo research published 《 Modulation of metal-azolate frameworks for the tunable release of encapsulated glycosaminoglycans》, the research content is summarized as follows. Glycosaminoglycans (GAGs) are biomacromols. necessary for the regulation of different biol. functions. In medicine, GAGs are important com. therapeutics widely used for the treatment of thrombosis, inflammation, osteoarthritis and wound healing. However, protocols for the encapsulation of GAGs in MOFs carriers are not yet available. Here, we successfully encapsulated GAG-based clin. drugs (heparin, hyaluronic acid, chondroitin sulfate, dermatan sulfate) and two new biotherapeutics in preclin. stage (GM-1111 and HepSYL proteoglycan) in three different pH-responsive metal-azolate frameworks (ZIF-8, ZIF-90, and MAF-7). The resultant GAG@MOF biocomposites present significant differences in terms of crystallinity, particle size, and spatial distribution of the cargo, which influences the drug-release kinetics upon applying an acidic stimulus. For a selected system, heparin@MOF, the released therapeutic retained its antithrombotic activity while the MOF shell effectively protects the drug from heparin lyase. By using different MOF shells, the present approach enables the preparation of GAG-based biocomposites with tunable properties such as encapsulation efficiency, protection and release.

10111-08-7, 1H-Imidazole-2-carbaldehyde, also known as 1H-Imidazole-2-carbaldehyde, is a useful research compound. Its molecular formula is C4H4N2O and its molecular weight is 96.09 g/mol. The purity is usually 95%.
1H-Imidazole-2-carboxaldehyde is a novel PTP1b inhibitor with potential application to treat type 2 diabetes.
1H-Imidazole-2-carboxaldehyde is a broad-spectrum antimicrobial that has been shown to inhibit the growth of bacteria by interfering with protein synthesis. It binds to the cytosolic protein and receptor molecule, which are involved in the activation of bacterial enzymes. Imidazole-2-carboxaldehyde reacts with anhydrous sodium and copper complex to produce hydrogen bonds, which prevent the formation of the nitrogen atoms necessary for cellular processes. This chemical also has biological properties such as glyoxal, which inhibits bacterial growth by reacting with amino groups on proteins., Recommanded Product: 1H-Imidazole-2-carbaldehyde

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem